Botulinum toxin is considered first-line treatment for focal hand dystonia in musicians. Mild, temporary weakness is a common accompaniment of effective injection. We present a unique case of delayed-onset, severe, prolonged weakness and atrophy in a patient with musician's dystonia, successfully treated with botulinum toxin for over 10 years, following injection of his usual muscles at his well-established dose. This pianist received botulinum toxin treatment for more than 10 years, with a stable response. Six weeks after an injection, he developed progressive severe weakness and atrophy of the affected forearm involving both injected and uninjected muscles. Weakness and atrophy took over one year without further injections to resolve. The clinical course and laboratory testing were not suggestive of brachial neuritis, plexopathy, or neuralgic amyotrophy. The literature contains rare case reports of severe weakness and atrophy after botulinum toxin injection, sometimes with delayed onset and sometimes affecting distant muscles. Frequently presenting with pain, such cases often have evidence of plexopathy or neuralgic amyotrophy which were absent in our patient. Clinicians should be aware of this rare potential severe adverse event associated with botulinum toxin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00702-024-02864-1 | DOI Listing |
Botulinum neurotoxin (BoNT) is a highly lethal toxin produced by the anaerobic bacterium Clostridium botulinum, which leads to nerve paralysis following poisoning. At present, there is no specific drug officially approved. Antibodies, particularly single-domain antibodies, represent safe and effective candidates for specific drugs against BoNT.
View Article and Find Full Text PDFJ Pharm Bioallied Sci
December 2024
Department of Clinical Dental Sciences, Ajman University, Ajman, United Arab Emirates.
Dentists' role in facial esthetics is growing, with advancements in cosmetic procedures, such as Botox and dermal fillers. Understanding the range of practitioners and their professional backgrounds is crucial for addressing risks. Data collection and analysis was done to retrieve scholarly papers using databases, such as PubMed and advanced Google search, and analyze.
View Article and Find Full Text PDFMayo Clin Proc Innov Qual Outcomes
April 2025
Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI.
Objective: To examine the most common patterns of pain and symptom management strategies among adults living with cerebral palsy (CP), and to determine if there are differences by pain phenotype or co-occurring neurodevelopmental disorders.
Patients And Methods: Federally insured beneficiaries were included if they had an ICD-9-CM/ICD-10-CM diagnosis code for CP (N=41,595). The study took place from January 10, 2024, to December 15, 2024.
Plast Reconstr Surg Glob Open
March 2025
Research and Innovation Hub, Innovation Aesthetics, London, United Kingdom.
Tremor Other Hyperkinet Mov (N Y)
March 2025
Department of Neurology, Consorci Sanitari de Terrassa, Barcelona, Spain.
Background: Essential tremor (ET) presents therapeutic challenges as oral therapies, are often partially effective and carry adverse effects. Deep Brain Stimulation and High-intensity Focused Ultrasound targeting the ventral intermediate thalamic nucleus show efficacy in managing ET; however, their cost and invasiveness deter some patients. Botulinum toxin infiltrations for ET in the upper limbs have been limited by adverse effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!